PC
JUNO

Passport Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Passport Capital’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,356
Closed -$232K – 235
2015
Q2 		$232K Buy
+4,356
New +$231K ﹤0.01% 171

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

Passport Capital's JUNO Position: Q3 2015 in Review

Passport Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 4,356 shares — an estimated $232K sold.

Passport Capital first reported a position in JUNO in Q2 2015 and held it in 1 quarter. The position peaked at $232K in Q2 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • Passport Capital reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Passport Capital sold 4,356 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $232K.
  • Passport Capital first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Passport Capital's Juno Therapeutics, Inc. position peaked at $232K in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Passport Capital's 13F filing for Q3 2015, filed 16 Nov 2015.